CAPTURA Phase Two Consortium
International Vaccine Institute (IVI) – As with CAPTURA I, the CAPTURA II is led by IVI’s Antimicrobial Resistance Department under the Epidemiology, Public Health, Impact (EPIC) Unit. IVI conducts overall project management and oversight, coordinates engagement between partners and countries, and leads AMC data quality and use, economic case for investment, and clinical engagement activities. IVI co-leads with consortium partners on AMR/U data quality and use, private sector engagement, and development and implementation of monitoring and evaluation frameworks, and supports advocacy and engagement with regional/global agencies for sustainability.
Brigham and Women’s Hospital (BWH) – Building upon the activities established together in CAPTURA I, Dr. John Stelling and team from the WHO Collaborating centre BWH co-leads AMR surveillance activities to improve data quality and use and support implementation of monitoring and evaluation framework in countries. BWH primarily provides technical assistance for capacity building for AMR data management and analysis as well as for AMR/U/C data quality and use across OH sectors.
SwipeRx – Holding the largest network of pharmacies in South East Asia, SwipeRx operates mobile platforms and connects more than 260,000 pharmacy professionals and students across Cambodia, Indonesia, Vietnam, and three additional markets in Southeast Asia. For CAPTURA, SwipeRx co-leads engagement with private sector pharmacies, supports generation of quality AMR/U data, implements monitoring and evaluation frameworks, and advocates for data sharing.
Heidelberg Institute of Global Health (HIGH) – One of the research institutes at the Faculty of Medicine at Heidelberg University, HIGH aims to contribute to improving the health of low and middle income populations worldwide, especially in Africa and Asia. HIGH works closely with governments and agencies on AMR advocacy and is an expert in developing program evaluation platforms, program design, and implementation research. HIGH co-leads the development and introduction of a monitoring and evaluating framework for effectiveness, impact and performance of AMR/U/C surveillance and advocacy and engagement with regional/global agencies for sustainability.
National Centre for Antimicrobial Stewardship (NCAS) – Established in 2015 as a Centre of Research Excellence at the Peter Doherty Institute for Infection and Immunity at the University of Melbourne and Royal Melbourne Hospital, NCAS is a group of healthcare professionals committed to promoting the rational use of antimicrobial drugs, providing education and training in antimicrobial stewardship (AMS) and aiding in implementation of antimicrobial stewardship programs. NCAS developed the National Antimicrobial Prescribing Survey (NAPS), which is an antimicrobial usage (AMU) surveillance platform that has been implemented as national programs in Australia, New Zealand and Canada, and piloted in several Fleming Fund-supported countries. NCAS co-leads AMU surveillance to improve data quality and use and supports implementation of M&E framework and technical assistance and capacity building activities aimed at improving AMR/U/C data quality and use.